2013-02-25 13:03:31 -
SEATTLE, WASHINGTON -- (Marketwire) -- 02/25/13 -- VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) has completed development of a new analysis product for cardiac Magnetic Resonance Imaging (CMR) based on its VMS(TM) platform. This VMS-CMR(TM) product enables a more rapid and equally accurate analysis of the right heart than conventional manual or semi-automated methods.
"Each year more than 10 million people undergo an MRI exam. A significant number of these procedures are heart-related. We developed the VMS-CMR(TM) heart analysis software solution to reduce the long analysis time for the right ventricle assessments using currently available MRI tools," stated Dr. George Adams, CEO of VentriPoint. "While our ultrasound products eliminate the need for CMR for most patients, we still realize that CMR assessments will be done prior to therapeutic interventions, such as surgery, and faster analysis would save valuable physicians' time."
The product uses the same knowledge-based-reconstruction (KBR) databases as the VMS-2DE(TM) and VMS-3DE(TM) echo products and can be applied to Congenital Heart Disease, Pulmonary Arterial Hypertension (PAH), left heart failure and normal hearts. The addition of VMS-CMR(TM) furthers Ventripoint products for the common cardiac imaging modalities. One nice benefit for hospitals using VentriPoint suite, is that reports will contain both ultrasound and MRI data, showing longitudinal data for a specific patient, making it easier to monitor a patient's progress.
The VMS-CMR(TM) product is undergoing clinical evaluations at Seattle Children's Hospital, Seattle, USA, The Hospital for Sick Children, Toronto, Canada and the Erasmus MC (Sophia) Children's Hospital, Rotterdam, Netherlands.
The Company anticipates submitting an application later this year for European CE Mark, Health Canada and FDA approvals using data from retrospective CMR studies to demonstrate equivalency with the current CMR analysis techniques.
About VentriPoint Diagnostics Ltd.
VentriPoint has created diagnostic tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS(TM) is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The Company has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS-2DE(TM) product.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
VentriPoint Diagnostics Ltd.
Dr. George Adams
(206) 283-0221, ext. 401 email@example.com
at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid= .. width="1" height="1" alt=" " border="0" />